Disease Severity Among Bio-Naive RA Patients on Csdmards

被引：0
|
作者：
Harrold, Leslie R. [1 ,2 ]
Griffith, Jenny [3 ]
Litman, Heather J. [2 ]
Feng, Hua [2 ]
Schlacher, Casey A. [3 ]
Kremer, Joel [4 ,5 ]
机构：
[1] Univ Massachusetts, Sch Med, Worcester, MA USA
[2] Corrona LLC, Waltham, MA USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Albany Med Coll, Albany, NY 12208 USA
[5] Ctr Rheumatol, Albany, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
543
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Assessing disease severity in bio-naive patients with RA on treatment with csDMARDs: insights from the Corrona Registry
    Harrold, Leslie R.
    Patel, Pankaj A.
    Griffith, Jenny
    Litman, Heather J.
    Feng, Hua
    Schlacher, Casey A.
    Kremer, Joel M.
    CLINICAL RHEUMATOLOGY, 2020, 39 (02) : 391 - 400
  • [2] Treatment Persistence Among Bio-naive Patients with Crohn's Disease Initiated on Ustekinumab and Adalimumab
    Pilon, Dominic
    Ding, Zhijie
    Manceur, Ameur M.
    Muser, Erik
    Zhdanava, Maryia
    Kinkead, Frederic
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S328 - S329
  • [3] Treatment persistence among bio-naive patients with Crohn's disease initiated on ustekinumab or adalimumab
    Zhdanava, Maryia
    Ding, Zhijie
    Manceur, Ameur M.
    Muser, Erik
    Lefebvre, Patrick
    Holiday, Christopher
    Lafeuille, Marie-Helene
    Pilon, Dominic
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (04) : 533 - 543
  • [4] PERSISTENCE AND DOSE TITRATION AMONG BIO-NAIVE PATIENTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB OR ADALIMUMAB
    Pilon, Dominic
    Ding, Zhijie
    Manceur, Ameur M.
    Zhdanava, Maryia
    Zhao, Ruizhi
    Holiday, Christopher
    Kachroo, Sumesh
    Lefebvre, Patrick
    GASTROENTEROLOGY, 2022, 162 (07) : S415 - S415
  • [5] Long-Term Persistence to Ustekinumab and Adalimumab Among Bio-Naive Patients With Crohn's Disease
    Zhdanava, Maryia
    Ding, Zhijie
    Manceur, Ameur M.
    Kachroo, Sumesh
    Holiday, Christopher
    Zhao, Ruizhi
    Izanec, James
    Pilon, Dominic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S571 - S572
  • [6] SURVIVAL OF BDMARDS IN BIO-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DURING THE FIRST YEAR OF THERAPY
    Aronova, E. S.
    Lukina, G. V.
    Glukhova, S. I.
    Gridneva, G. I.
    Kudryavceva, A. V.
    Kovalenko, P. S.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S353 - S353
  • [7] Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry
    Leslie R. Harrold
    Pankaj A. Patel
    Jenny Griffith
    Heather J. Litman
    Hua Feng
    Casey A. Schlacher
    Joel M. Kremer
    Clinical Rheumatology, 2020, 39 : 391 - 400
  • [8] Adalimumab was more effective in the patients with bio-naive and early Crohn's disease
    Hisamatsu, T.
    Matsuoka, K.
    Naganuma, M.
    Miyoshi, J.
    Inoue, N.
    Yajima, T.
    Mizuno, S.
    Saigusa, K.
    Nakazato, Y.
    Mori, K.
    Takeshita, K.
    Nanki, K.
    Kiyohara, H.
    Iwao, Y.
    Ogata, H.
    Kanai, T.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S305 - S305
  • [9] Leukocyte Adhesive Function as Potential Predictive Marker for Treatment Response to Vedolizumab Among Bio-naive Patients with Crohn's Disease
    Liu, J.
    Cheng, Q.
    Cao, Q.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1077 - I1078
  • [10] Effectiveness and safety of Adalimumab Biosimilars in Bio-naive patients with Inflammatory Bowel Disease: The Galician experience
    Villaamil, P. Vega
    Rey, M. T. Vazquez
    Rey, I. Baston
    Galego, M. Ayude
    Campos, A. Carmona
    Lopez, A. M. Baz
    Arriero, G. Molina
    Barcia, M. J. Ruiz
    Exposito, C. Regueiro
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1622 - I1622
12345